| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.UROLONC.2008.11.018 |
| P698 | PubMed publication ID | 19181544 |
| P2093 | author name string | Wei Qu | |
| Li-Ming Wang | |||
| Li-Li Fu | |||
| Mei-Sheng Zhou | |||
| Yin-Dong Kang | |||
| Zhen-Hao Hua | |||
| P2860 | cites work | Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals | Q22122053 |
| The Bcl-2 apoptotic switch in cancer development and therapy | Q24620437 | ||
| Cell cycle sibling rivalry: Cdc2 vs. Cdk2 | Q28279559 | ||
| Epigenetics in human disease and prospects for epigenetic therapy | Q29547437 | ||
| Histone modification enzymes: novel targets for cancer drugs | Q34322087 | ||
| Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 | Q36017473 | ||
| Killing cancer cells by flipping the Bcl-2/Bax switch. | Q36197245 | ||
| Up-regulation of p21WAF1/Cip1 by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells | Q39999694 | ||
| Antitumor effect of dsRNA-induced p21(WAF1/CIP1) gene activation in human bladder cancer cells | Q40001406 | ||
| Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest | Q40268478 | ||
| Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells | Q40339240 | ||
| Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells | Q40353361 | ||
| Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells | Q40483365 | ||
| Histone deacetylase inhibitors specifically kill nonproliferating tumour cells | Q40538874 | ||
| Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116. | Q40540679 | ||
| p21--negative regulator of the cell cycle | Q41226557 | ||
| Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo | Q45119904 | ||
| Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. | Q53436869 | ||
| G1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A + Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of beta-catenin. | Q53621630 | ||
| P433 | issue | 6 | |
| P921 | main subject | bladder cancer | Q504775 |
| entinostat | Q1281020 | ||
| P304 | page(s) | 648-654 | |
| P577 | publication date | 2009-01-31 | |
| P1433 | published in | Urologic Oncology | Q2113446 |
| P1476 | title | Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells | |
| P478 | volume | 28 |
| Q39286205 | Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers |
| Q92350755 | Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems |
| Q38560926 | Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma |
| Q37925846 | Entinostat for treatment of solid tumors and hematologic malignancies |
| Q35119480 | Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer |
| Q39100081 | HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions |
| Q38762886 | HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells |
| Q33893161 | Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells |
| Q64121548 | Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway |
| Q37889246 | Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. |
| Q36734390 | Histone deacetylases and mechanisms of regulation of gene expression |
| Q64965996 | MS-275 potentiates the effect of YM-155 in lung adenocarcinoma via survivin downregulation induced by miR-138 and miR-195. |
| Q34002839 | Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis |
| Q21198868 | Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents |
| Q34703660 | PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma |
| Q64039896 | Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer |
| Q37728062 | SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection |
| Q38902594 | Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer. |
| Q30368366 | The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines. |
| Q57028508 | Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma |
| Q53294619 | [Signal transduction in urothelial cancer: how exactly do we know the targets for targeted therapy?]. |
Search more.